LC said Her-Vaxx has shown greater safety signal. It has the same or potential better efficacy.
The other company product makes 7-8B. It has been approved for a long time.
Imugene has a easier runway of what to do Next: Further studies or Discussion with regulator.
Note: Her-Vaxx is a study to treat Gastric Cancer.
Gastric Cancer is mostly common to Asian people.
Imugene's Leslie Chong says positive HER-Vaxx data 'validates entire platform'
-
- There are more pages in this discussion • 282 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.9¢ |
Change
0.000(0.00%) |
Mkt cap ! $431.8M | |||
| Open | High | Low | Value | Volume |
| 5.9¢ | 5.9¢ | 5.6¢ | $1.037M | 17.94M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 1882949 | 5.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.9¢ | 399643 | 3 |
View Market Depth
| Last trade - 16.10pm 21/06/2024 (20 minute delay) ? |
| IMU (ASX) Chart |